Clinical Significance of CCR4 Expression in Adult T-Cell Leukemia/Lymphoma: Its Close Association with Skin Involvement and Unfavorable Outcome1

Takashi Ishida, Atae Utsunomiya, Shinsuke Iida, Hiroshi Inagaki, Yoshifusa Takatsuka, Shigeru Kusumoto, Genji Takeuchi, Shigeki Shimizu, Masato Ito, Hirokazu Komatsu, Atsushi Wakita, Tadaaki Eimoto, Kouji Matsushima, and Ryuzo Ueda2

Department of Internal Medicine and Molecular Science [T. I., S. I., M. I., H. K., R. U.] and Department of Clinical Pathology [H. I., S. S., T. E.], Nagoya City University Graduate School of Medical Science, Nagoya 467-8601; Department of Hematology, Imamura Bun-in Hospital [A. U., Y. T.]; Department of Hematology, Shizuoka Saiseikai General Hospital [S. K., G. T.]; Division of Transfusion Medicine, Nagoya City University Hospital [A. W.]; and Department of Molecular Preventive Medicine and Core Research and Evolutional Science and Technology, University of Tokyo [K. M.], Tokyo, Japan

ABSTRACT

Adult T-cell leukemia/lymphoma (ATLL) is a distinct clinical entity among mature T-cell neoplasms, and its causative agent has been confirmed to be long-term infection by human T-lymphotropic virus type 1. A recent study demonstrated frequent expression of a chemokine receptor, CC chemokine receptor (CCR)4, which is known as a Th2 marker but not CXC chemokine receptor (CXCR)3, which is known as a Th1 marker, among both ATLL- and human T-lymphotropic virus type 1-immortalized T cells. In this study, immunostaining analysis for CCR4 and CXCR3 expression in ATLL cells obtained from 103 patients with ATLL was performed, and the clinical parameters and overall survival of the CCR4-positive and -negative cases were compared. Ninety-one (88.3%) of the 103 cases were positive for CCR4 staining, whereas only 5 (4.9%) were positive for CXCR3 staining. Positivity for CCR4 was significantly associated with skin involvement (P < 0.05), although there were no significant differences in clinical characteristics between the CCR4-positive and -negative cases at the time of initial diagnosis. CCR4+ ATLL cells may accumulate in the skin because of the expression of a CCR4 ligand, thymus and activation-regulated chemokine (TARC), on normal and inflamed cutaneous endothelia. As for survival analysis, positivity for CCR4 expression was extracted as an unfavorable prognostic factor as well as other factors, including the presence of B symptoms and extranodal involvement of more than one site. Multivariate analysis confirmed that CCR4 expression was an independent and significant prognostic factor (P < 0.05). Thus, our finding may provide a novel insight into not only the biological but also the clinical features of ATLL.

INTRODUCTION

Chemokines belong to a superfamily of small, cytokine-like proteins that induce cytoskeletal rearrangement, firm adhesion to endothelial cells, and directional migration of the leukocytes by interacting with G protein-coupled receptors (1–3). This leukocyte trafficking, which is critically regulated by chemokines and their receptors, shares many similarities with tumor cell migration and metastasis. For example, CXCR4, a chemokine receptor, is expressed more abundantly in breast cancer tissues than in normal breast tissues; its ligand, CXCL12, is expressed in various organs such as the lymph nodes, bone marrow, and lungs, where breast cancer cells tend to metastasize (4).

ATLL1 is a peripheral T-cell neoplasm. ATLL is most often composed of highly pleomorphic lymphoid cells and is caused by HTLV-1 (5). In ATLL, leukemic cells frequently infiltrate into organs such as the lymph nodes, spleen, liver, and skin. Various HTLV-1-associated inflammatory diseases are also commonly characterized by the infiltration of HTLV-1+ T cells into target organs (6). It is thus conceivable that chemokines and their receptors play important roles in tissue infiltration of ATLL cells and HTLV-1+ T cells, analogous to the assumed mechanism in metastatic breast cancer. In addition, it has generally become accepted that the expression profile of chemokine receptors in normal T-cell subsets is associated with the profile of cytokine secretion. Specifically, CCR4, CCR3, and CCR8 are selective markers of the Th2 phenotype, whereas CXCR3 is a selective marker of the Th1 phenotype (7–12).

Received 7/8/02; revised 3/12/03; accepted 3/21/03.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was partly supported by the Ministry of Education, Science, Sports and Culture, Japan (to S. I., R. U.).

2 To whom requests for reprints should be addressed, at Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Phone: 81-52-853-8216; Fax: 81-52-852-0849; E-mail: ueda@med.nagoya-cu.ac.jp.

The abbreviations used are: ATLL, adult T-cell leukemia/lymphoma; HTLV-1, human T-lymphotropic virus type 1; MF, mycosis fungoides; mAb, monoclonal antibody; PBMC, peripheral blood mononuclear cell; RT-PCR, reverse transcription-PCR; PS, performance status; LDH, lactate dehydrogenase; Hb, hemoglobin level; Plt, platelet count; CNS, central nervous system; OS, overall survival; HR, hazard ratio; CI, confidence interval; TARC, thymus and activation-regulated chemokine; MCP, monocyte chemotactic protein-1; Mig, monokine induced by IFNγ; CLA, cutaneous lymphocyte antigen; MDC, macrophage-derived chemokine; CXCL, CXC chemokine ligand; CCR, CC chemokine receptor.
although some controversy exists. As in the case of normal T-cell subsets, there is differential expression of chemokine receptors in T-cell-derived tumors. The pattern of chemokine receptor expression in T-cell-derived non-Hodgkin's lymphoma was characterized previously (13). In ATLL, CXCR3 was not expressed (zero of two), whereas the expression of CCR4, CCR5, Mig, TARC, and MCP-2 was not studied. Interestingly, CCR4 expression was seen in all (5 of 5) patients with large-cell-transformed MFs but in only 1 of the 7 patients with nontransformed MFs (13). This suggests that CCR4-expressing T-cell tumors may acquire a certain growth advantage similar to tumor progression in MF. ATLL develops as a result of multistep tumorigenesis and results in an unfavorable outcome because of rapid deterioration of the disease. We investigated 103 cases with ATLL to analyze the biological and clinical significance of CCR4 and CXCR3 expression by an immunostaining procedure.

MATERIALS AND METHODS

mAbs against Chemokine Receptors and CLA. We used murine mAbs against CCR4 (KM2160; kindly provided by Kyowa Hakko Kogyo, Inc., Tokyo, Japan) and CXCR3 (1C6; BD Pharmingen, San Diego, CA; Refs. 7, 14, 15) and rat mAb against CLA (HECA452; BD Pharmingen; Ref. 16). The KM2160 mAb recognizes the NH2-terminal portion (amino acids 12–29) of the CCR4 molecule.

Cell Lines and Viable Patient Samples. HUT102, ATL102, and ATN-1 are human T-cell lines established from patients with ATLL (17–19). They have clonal integration of HTLV-1, as determined by Southern blot analysis. MT-2 is a human T-cell line transformed by infection of HTLV-1 (18–20). PBMCs were isolated from two patients diagnosed as having acute-type ATLL and three healthy adult volunteers upon informed consent. Lesional skin, lymph node, and bone marrow tissues were obtained from four patients with acute-type ATLL upon informed consent and used for RNA extraction in addition to histological examination.

Flow Cytometric Analysis. After blocking surface Fc receptors by murine normal serum (Dako, Kyoto, Japan), 1 × 10⁶ cells were incubated at 4°C with biotin-conjugated anti-CCR4 or isotype control mAb (MOPC-21; BD Pharmingen) for 30 min, washed, and resuspended in PBS. Then, the cells were incubated with streptavidin-FITC conjugate (BD Pharmingen) for 30 min, washed, resuspended in PBS, and analyzed by FACScan with the aid of CELLQuest software (Becton Dickinson, San Jose, CA). Intracellular cytokines of ATLL cell lines were analyzed after stimulation with phorbol 12-myristate 13-"
acetate, ionomycin, and Brefeldin A for 4 h followed by fixation and permeabilization. Double staining for the intracellular cytokine IFN-γ, with FITC and interleukin 4 with phycoerythrin, was performed (21).

RT-PCR. Total RNA was prepared from the cells or tissues. After incubation with DNase I, 1 μg of the total RNA was reverse transcribed and dissolved in a total volume of 42 μl as a first-strand cDNA solution. Two μl of this solution was used to amplify CCR4, TARC, MDC, or β-actin mRNA (22). The oligonucleotide primers were as follows: for CCR4, sense, 5'-CCCTCGATGAAAGCATATAC-3' and antisense, 5'-GT-GAAACAAAAGCCAGAGTTT-3'; for TARC, sense, 5'-AG-TACTTCAAGGGAGCCATT-3' and antisense, 5'-AGACCTTAAATCTGGGCCCTT-3'; for MDC, sense, 5'-AACACTTTGAGGGGTATTAA-3' and antisense, 5'-TAGGGTTATATTGAAGGGGACC-3'.

Patient Selection. This study included 103 patients with ATLL diagnosed between 1989 and 2002 at four independent hospitals (Imamura Bun-in Hospital, Nagoya City University Hospital, Shizuoka Saiseikai General Hospital, and Ensyu General Hospital). The diagnosis and classification of clinical subtypes of the ATLL were made according to the criteria proposed by the Japan Lymphoma Study Group (23). Clinical variables analyzed in this study included age, sex, clinical subtype, presence or absence of B symptoms and extranodal involvement, PS, serum LDH level, serum calcium level, WBC count, abnormal lymphocyte count, Hb and Plt of the peripheral blood, surface phenotypic markers (CD4, CD8, CD30, and CLA), involved organs (lymph node, bone marrow, peripheral blood, liver, spleen, gastrointestinal tract, lung, CNS, bone, skin, ascites, pericardial effusion, pleural effusion, nasopharynx, Waldeyer’s tonsillar ring, kidney, eye, muscle, and mammary gland tissues), and clonal integration of HTLV-1 provirus in the genomic DNA of the tumor cells as determined by Southern blot analysis. We used the clinical data at the time, when the initial biopsy was performed. Although the treatment for ATLL cases enrolled in this study were variable, combination chemotherapy containing doxorubicin such as RCM protocol (24), LSG15 protocol (25), and cyclophosphamide-doxorubicin-vincristine-prednisone regimen were applied for most patients.

Histopathology. Tissue biopsy of the lesional organs was performed to obtain sufficient amount of materials after informed consent was obtained from the patients. Specimens were fixed in 10% buffered formalin and embedded in paraffin. The morphological classification was performed according to the WHO Classification of Tumors (5) with slight modification. We classified the 103 ATLL samples into the following five groups: (a) pleomorphic large cell type; (b) pleomorphic medium-sized cell type; (c) pleomorphic small-sized cell type; (d) anaplastic large cell lymphoma-like type; and (e) Hodgkin lymphoma-like type.

Immunostaining. The immunostaining analysis was performed with the aid of a SS MultiLink Detection kit, horseradish peroxidase/3,3′-diaminobenzidine (BioGenex Laboratories, San Ramon, CA) using formalin-fixed, paraffin-embedded sections. We immunostained for both CCR4 and CXCR3 in several nearly normal lymph nodes and in the lesional tissues of 103 patients with ATLL. Immunoabsorption with the CCR4 antigen peptide of the CCR4-positive specimens resulted in negative stains (data not shown). Cell pellets that had been prepared from 1 × 10⁷ ATLL cells were also fixed with formalin, embedded in paraffin, and used for immunostaining. We defined a specimen

---

**Fig. 3** Immunostaining for CCR4 and CXCR3 in normal reactive lymph nodes. Immunostaining was performed on formalin-fixed, paraffin-embedded hyperplastic lymph node sections. A and B, immunostaining for CCR4 using KM2160 mAb. A small percentage of the T cells in the paracortex area show positivity for CCR4. C and D, immunostaining for CXCR3 using 1C6 mAb. Nearly half of the interfollicular T cells were stained. A and C, magnification, ×40; B and D, magnification, ×100.
as being positive for CCR4 or CXCR3 if >10% of the apparent tumor cells were stained with the respective antibody.

**Statistical Analysis.** The significance of differences between the CCR4-positive and -negative groups was examined with the Fisher’s exact test or the Mann-Whitney U test. Patients’ survival data were analyzed with the Kaplan-Meier method and were compared using the log-rank and Breslow-Gehan-Wilcoxon tests. Univariate and multivariate analyses were performed with the Cox proportional hazard regression model, and variables used in the latter analysis were selected with the stepwise method. Data were analyzed with the aid of Statview software (version 5.0; SAS Institute, Cary, NC). In this study, \( P < 0.05 \) was considered as significant.

**RESULTS**

**Frequent Expression of Surface CCR4 among ATLL-derived Cell Lines.** We evaluated the surface expression of CCR4 on ATLL cell lines (HUT102, ATN-1, and ATL102) and on a HTLV-1-transformed cell line (MT-2) by both flow cytometric and immunostaining analyses (Fig. 1). Three (75%) of the four cell lines (ATL102, MT-2, and ATN-1) showed membrane staining and granular cytoplasmic staining, and these findings were consistent with the data obtained by flow cytometric analysis. We next examined to see whether these ATL cells secrete Th2 cytokines. However, there was no fundamental difference in the profile of cytokine production among these four ATLL cell lines, i.e., all four lines were of the Th0 subtype (data not shown) as previously reported by other investigators (26, 27).

**mRNA Expression of CCR4 and Its Ligands, TARC and MDC, in ATLL Cells.** The mRNA expression of CCR4 and its ligands, TARC and MDC, in four cell lines was investigated by RT-PCR analysis. On RT-PCR, the ATN-1, MT-2, and ATL102 cell lines showed strong bands for CCR4 mRNA, whereas the HUT102 line showed no visible band at our sensitivity as shown in Fig. 2A. The ATL102 line also showed strong

### Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Total number</th>
<th>103</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr), median (range)</td>
<td>61 (37–88)</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>63/40</td>
</tr>
<tr>
<td>Clinical subtype*</td>
<td>Acute 77 (75.5%); Lymphoma 17 (16.7%); Chronic 3 (2.9%); Smoldering 5 (4.9%)</td>
</tr>
<tr>
<td>Histological classification</td>
<td>Pleomorphic large 55 (53.4%); Pleomorphic medium 33 (32.0%); Pleomorphic small 9 (8.7%); ALCL-like# 5 (4.9%); HL-like 1 (1.0%)</td>
</tr>
<tr>
<td>B symptoms*</td>
<td>Present 34 (33.3%); Absent 68 (66.7%)</td>
</tr>
<tr>
<td>PS*</td>
<td>0 18 (17.6%); 1 41 (40.2%); 2 20 (19.6%); 3 19 (18.6%); 4 4 (3.9%)</td>
</tr>
<tr>
<td>LDH (upper limit of normal), median (range)</td>
<td>1.86 (0.59–24.65)</td>
</tr>
<tr>
<td>Ca (mg/dl), median (range)</td>
<td>9.6 (8.0–19.4)</td>
</tr>
<tr>
<td>WBC (×10^3/μl), median (range)*</td>
<td>8.20 (1.6–208.6)</td>
</tr>
<tr>
<td>Hb (g/dl), median (range)</td>
<td>13.2 (6.3–16.9)</td>
</tr>
<tr>
<td>Platelets (×10^3/μl), median (range)*</td>
<td>202.5 (19.5–443)</td>
</tr>
<tr>
<td>CD4 CD8</td>
<td>CD4+CD8+ 91 (88.3%); CD4+CD8+ 8 (7.8%); CD4+CD8+ 3 (2.9%); CD4+CD8+ 1 (1.0%)</td>
</tr>
<tr>
<td>CD30*</td>
<td>+ 25 (26.0%); - 71 (74.0%)</td>
</tr>
<tr>
<td>CCR4</td>
<td>+ 91 (88.3%); - 12 (11.7%)</td>
</tr>
<tr>
<td>CXCR3</td>
<td>+ 5 (4.9%); - 98 (95.1%)</td>
</tr>
<tr>
<td>CLA*</td>
<td>+ 17 (17.3%); - 81 (82.7%)</td>
</tr>
<tr>
<td>Clonal integration of HTLV-1</td>
<td>+ 35 (34.0%); - 0</td>
</tr>
<tr>
<td>Not tested or unknown</td>
<td>68 (66.0%)</td>
</tr>
</tbody>
</table>

*1 case was not evaluated.

#ALCL, anaplastic large-cell lymphoma; HL, Hodgkin lymphoma.
*2 cases were not evaluated.
*3 cases were not evaluated.
*7 cases were not evaluated.
*5 case were not evaluated.
bands for TARC and MDC mRNA, whereas the ATN-1 and MT-2 lines showed a weak band for MDC mRNA. Accordingly, all ATLL-related cell lines expressing CCR4 were positive for MDC expression at the mRNA level but were not always positive for TARC expression. We next carried out RT-PCR analysis of CCR4 expression in PBMCs derived from healthy adult volunteers and from ATLL patients and in tissues where leukemic cells had infiltrated. All PBMCs derived from the healthy adult volunteers expressed the mRNA for CCR4, whereas they did not express the mRNA for MDC nor TARC. Similarly, all PBMC samples derived from the ATLL patients expressed the mRNA for CCR4. However, among organs infiltrated by ATLL cells, only the skin showed signals for expression of its ligands. Sample number 8 showed weak TARC mRNA expression, and sample number 9 showed strong TARC and weak MDC expression as shown in Fig. 2B.

Fig. 4  A representative lymph node finding of a patient with lymphoma type ATLL. A, the majority of tumor cells stained for CCR4. Most cells show membrane staining and granular cytoplasmic staining (CCR4 immunostaining, ×400). B, proliferation of large atypical cells with irregular and pleomorphic nuclei. This case was classified as pleomorphic large-cell type (H&E staining, ×400). C, the same tumor cells of this case are negative for CXCR3 (CXCR3 immunostaining, ×400).

CCR4 and CXCR3 Expression in Nearly Normal Lymph Node. In reactive lymph nodes, a few interfollicular T cells were noted to be positive for CCR4 by immunostaining analysis, comprising 3–7% of all cells in the paracortex area (Fig. 3, A and B). On the contrary, many interfollicular T cells were positive for CXCR3, comprising 30–60% of all cells in the paracortex area (Fig. 3, C and D). B cells localized in the follicles, mantle zones, and marginal zones were negative for CCR4 and CXCR3. These results are consistent with the data reported previously (7, 10).

Clinical Features of the 103 ATLL Patients and Immunostaining of Their Specimens for CCR4 and CXCR3. Among the 103 ATLL patients, there were 63 males and 40 females with an age range of 37–88 years (median age, 61 years). The patients’ clinical characteristics are summarized in Table 1. Specimens derived from 91 (88.3%) of the 103 cases
were positive for CCR4, and specimens derived from only 5 cases (4.9%) were positive for CXCR3. Immunostaining pictures of lesional tissues from two representative CCR4+ patients are shown in Figs. 4 and 5. In most specimens positive for CCR4, nearly all neoplastic cells showed positive staining by immunohistochemistry as shown in Figs. 4A and 5C. Moreover, the CCR4 expression in skin tumor cells did not vary irrespective of their localization in the skin. The OS curve of all ATLL cases enrolled in this study is shown in Fig. 6A. The 50% survival ± SE was 10.5 ± 0.6 months.
Comparison of the Clinical Characteristics of the CCR4+ and CCR4− Cases. The patient characteristics based on the CCR4 status are summarized in Table 2. Surface CD4, CD8, and CD30 positivity were not associated with CCR4 expression. Regarding CLA expression, although no statistically significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belonged to the CCR4-positive group. The significant association with CCR4 expression was determined by the Fisher’s exact test, it was of interest that all of the CLA-positive cases belong...
Table 4  Involvement sites according to CLA expression

<table>
<thead>
<tr>
<th>Total number</th>
<th>CLA+ ATLL</th>
<th>CLA- ATLL</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>17</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>Involvement sites</td>
<td>LN²</td>
<td>13 (76.5%)</td>
<td>72 (88.9%)</td>
</tr>
<tr>
<td>Extranodal involvement</td>
<td>BM</td>
<td>8 (47.1%)</td>
<td>42 (51.9%)</td>
</tr>
<tr>
<td></td>
<td>PB</td>
<td>13 (76.5%)</td>
<td>62 (76.5%)</td>
</tr>
<tr>
<td></td>
<td>Liver</td>
<td>0 (0%)</td>
<td>16 (19.8%)</td>
</tr>
<tr>
<td></td>
<td>Spleen</td>
<td>5 (29.4%)</td>
<td>24 (29.6%)</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal tract</td>
<td>4 (23.5%)</td>
<td>20 (24.7%)</td>
</tr>
<tr>
<td></td>
<td>Lung</td>
<td>1 (5.9%)</td>
<td>3 (3.7%)</td>
</tr>
<tr>
<td></td>
<td>CNS</td>
<td>0 (0%)</td>
<td>2 (2.5%)</td>
</tr>
<tr>
<td></td>
<td>Bone</td>
<td>1 (5.9%)</td>
<td>2 (2.5%)</td>
</tr>
<tr>
<td></td>
<td>Skin</td>
<td>9 (52.9%)</td>
<td>16 (19.8%)</td>
</tr>
<tr>
<td>≥2 sites</td>
<td>13 (76.5%)</td>
<td>60 (74.1%)</td>
<td>&gt;0.9999</td>
</tr>
<tr>
<td>≥3 sites</td>
<td>7 (41.2%)</td>
<td>45 (55.6%)</td>
<td>0.2997</td>
</tr>
</tbody>
</table>

*LN, lymph node; BM, bone marrow; PB, peripheral blood; CNS, central nervous system.

Adverse factors with respect to the patients’ survival: PS ≥ 2; presence of B symptoms; extranodal involvement of more than one site; serum LDH level > upper limit of normal; serum Ca level ≥ 11.0 mg/dl; and positive CCR4 expression (Table 5). Multivariate analysis demonstrated the presence of B symptoms (HR = 2.425; 95% CI, 1.517–3.878; P = 0.0002), extranodal involvement of more than one site (HR = 2.106; 95% CI, 1.213–3.656; P = 0.0081), and positive CCR4 expression (HR = 2.197; 95% CI, 1.080–4.469; P = 0.0298) to be independent and significant unfavorable prognostic factors (Table 5).

DISCUSSION

In this paper, we reported that most ATLL cells were positive for CCR4 by immunostaining analysis, thus supporting the previous finding that showed its mRNA expression (30). In the normal condition, CCR4 is selectively expressed in CD4⁺ memory T cells (14), and CCR4 is expressed in a few circulating peripheral T cells (13, 15, 31–33); in contrast, CXCR3 is expressed in many circulating peripheral T cells (11, 15, 32). These findings show that there are similarities between circulating T-cell subset and interfollicular T cells in normal lymph nodes with respect to the distribution of CCR4 and CXCR3 positivity. Our data may suggest that the origin of ATLL cells in most patients is CCR4-positive T cells, or ATLL is more likely to develop in those HTLV-1 carriers who have altered immune regulation leading to increased numbers of CCR4-positive-infected cells. Interestingly, however, the profile of cytokine production in the CCR4-positive and -negative ATLL cell lines are all Th0 subtype. This indicates that the cytokine profiles of ATLL cells and HTLV-1-immortalized T cells do not simply shift to the Th2 phenotype (26, 27), suggesting that ATLL cells show an aberrant phenotype or they abnormally express CCR4 for unknown reasons probably associated with tumorigenesis.

In our study, the CCR4⁺ ATLL was significantly associated with the skin involvement, and only the involved skin tissues showed expression of the CCR4 ligand, TARC. Recent studies have also confirmed TARC to be expressed on normal and inflamed cutaneous endothelia (33, 34). The skin involvement was also associated with CLA expression in our study. In fact, recent studies have also revealed that most CLA⁺ memory CD4⁺ lymphocytes express high levels of CCR4, whereas mAb against CCR4 also recognized a smaller number of CLA⁻ peripheral blood memory CD4⁺ lymphocytes (34). Because the relationship between CCR4 and CLA expression was not statistically confirmed and some CCR4⁺CLA⁻ ATLL cases obviously had skin lesions in our study, our finding suggests that CCR4 and TARC participate in skin-specific recruitment of ATLL cells and are consistent with a selective role for CCR4 in skin lymphocyte homing (35).

We also demonstrated that CCR4 expression in ATLL cells as detected by immunostaining is an independent and statistically significant prognostic factor. The reason why CCR4 expression in ATLL cells contributes to poorer outcome in ATLL remains unclear. CCR4 positivity was significantly associated with skin involvement, whereas the presence of skin lesions itself did not affect prognosis. In ATLL, multistep oncogenic events are involved in the development of the full malignant phenotype in HTLV-1-infected cells after a long latency. The cumulative incidence of ATLL is estimated to be ~2.5% among HTLV-1 carriers in Japan, and the median age at the time of diagnosis of ATLL is ~55 years. CCR4 expression itself does not seem to be necessary for early development of ATLL because a small percentage of the ATLL cases in our study were negative for CCR4 expression. In patients with chronic or smoldering variants of ATLL, their neoplastic cells are usually small with minimal cytological atypia, and they occasionally develop into acute crisis, resulting in histological and clinical progression. As in the case of MF, it can be hypothesized that ATLL cells acquire the ability to express CCR4 as the tumors expand, resulting in aggressive behavior and poor prognosis. However, there was no significant relationship between the clinical subtype of ATLL and CCR4 expression. As for the histological classification, there was no significant relationship between histological large-cell transformation and CCR4 expression in ATLL in our study. In this regard, ATLL differs from MF in which CCR4 expression is associated with large-cell transformation (13). This suggests that CCR4 expression may represent certain biological behaviors rather than evident clinical and/or histological progression. CCR4 expression did not seem to reflect the tumor burden because CCR4 expression was not associated with a high LDH level. An interesting hypothesis is that an autocrine loop via the CCR4-ligand system with respect to growth stimulation may exist in addition to probable paracrine CCR4 activation through intermixed macrophages and adjacent blood vessels. From this point of view, it is of interest that all ATLL cell lines expressing CCR4 were positive for MDC expression. As a matter of fact, it has been demonstrated that I-309, a member of the family of CC chemokines, inhibits apoptosis of ATLL cells, and may substantially contribute to their growth through an autocrine loop (36). In small cell lung cancer, a regulation mechanism of cellular proliferation through CXCR4 was reported previously (37). Our novel findings that CCR4 expression on ATLL cells is closely associated with skin involvement and with an unfavorable outcome will provide new insights into understanding the pathogenesis of ATLL, although its underlying mechanism, particularly in terms of biological behavior, remains to be clarified in additional
investigations. In addition, specifically targeted therapy against the CCR4 molecule using anti-CCR4 mAb could be developed as an alternative treatment for the patients with ATLL.

ACKNOWLEDGMENTS

We thank Seizo Nagaya, Chika Ando, Satomi Ozeki, and Chiori Fukuyama for their skilful technical assistance and Dr. Ayumu Itô of the Division of Internal Medicine, Enyu General Hospital (Hamamatsu, Japan) for providing us with clinical information on the patients. We also thank Kyowa Hakko Kogyo Incorporation (Tokyo) for providing us with clinical information on the patients. We thank Seizo Nagaya, Chika Ando, Satomi Ozeki, and Chiori Fukuyama for their skilful technical assistance and Dr. Ayumu Itô of the Division of Internal Medicine, Enyu General Hospital (Hamamatsu, Japan) for providing us with clinical information on the patients.

REFERENCES


22. Ponte, P., Ng, S. Y., Engle, J., Gunn, P., and Kedes, L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA
Clinical Significance of CCR4 Expression in Adult T-Cell Leukemia/Lymphoma: Its Close Association with Skin Involvement and Unfavorable Outcome

Takashi Ishida, Atae Utsunomiya, Shinsuke Iida, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/9/10/3625

Cited articles
This article cites 36 articles, 16 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/9/10/3625.full.html#ref-list-1

Citing articles
This article has been cited by 41 HighWire-hosted articles. Access the articles at:
/content/9/10/3625.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.